Nobis Nobis Cartel windows 7 home premium activation key 70-290

Analysis of High-dose Intravenous Immunoglobulin Therapy in Patients

High-dose intravenous immunoglobulin (IVIG) therapy is used in patients with severe autoimmune blistering diseases that are refractory to standard immunosuppressive therapy. To determine the efficacy and frequency of adverse events of IVIG therapy, we retrospectively analysed data for 16 patients with pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, bullous pemphigoid and paraneoplastic bullous pemphigoid. Frequency of adverse reactions and efficacy of IVIG were analysed over time with a scoring system for every 6 months of IVIG therapy. Headache (43.8%) and fatigue (43.8%) were the most common side-effects recorded; serious adverse reactions did not occur. There was good overall efficacy, as measured by clinical response rates using a clinical score, as well as indicated by a mean reduction of 75.8% in the starting steroid dose.

Full article available at: http://www.ncbi.nlm.nih.gov/pubmed/23073990?dopt=Abstract

Geplaatst in Around the Globe, News and Information

JOIN TODAY!

The P/P Registry has been approved by the Western Institutional Review Board (WIRB) and is actively enrolling participants.

ENGLISH VERSION